For the quarter ending 2025-09-30, BNGO made $7,367,000 in revenue. -$8,503,000 in net income. Net profit margin of -115.42%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 7,367,000 | 6,733,000 | 6,457,000 | 8,466,000 |
| Product | 3,842,000 | 3,150,000 | - | - |
| Product And Service Other | 155,000 | 106,000 | - | - |
| Total cost of revenue | 3,997,000 | 3,256,000 | 3,519,000 | 5,345,500 |
| Research and development | 2,844,000 | 2,931,000 | 2,370,000 | 6,627,500 |
| Selling, general and administrative | 9,064,000 | 8,346,000 | 9,033,000 | 15,417,000 |
| Intangible assets and other long-lived assets impairment | 0 | 0 | - | 59,666.667 |
| Restructuring costs | 0 | 0 | - | 2,518,500 |
| Total operating expenses | 11,908,000 | 11,277,000 | 11,403,000 | 24,652,500 |
| Loss from operations | -8,538,000 | -7,800,000 | -8,465,000 | -21,532,000 |
| Interest income | 268,000 | 277,000 | 290,000 | 634,000 |
| Other income (expense) | -219,000 | 676,000 | 5,080,000 | -4,884,000 |
| Total other income (expense) | 49,000 | 953,000 | 5,370,000 | -4,250,000 |
| Loss before income taxes | -8,489,000 | -6,847,000 | -3,095,000 | -25,782,000 |
| Provision for income taxes | 14,000 | 10,000 | 7,000 | -8,500 |
| Net loss | -8,503,000 | -6,857,000 | -3,102,000 | -25,773,500 |
| Net loss per share, basic (in dollars per share) | -1.59 | -1.99 | -1.15 | -43.685 |
| Net loss per share, diluted (in dollars per share) | -1.59 | -1.99 | -1.15 | -43.685 |
| Weighted-average common shares outstanding, basic (in shares) | 5,338,000 | 3,441,000 | 2,694,000 | -76,091,000 |
| Weighted-average common shares outstanding, diluted (in shares) | 5,338,000 | 3,441,000 | 2,694,000 | -76,091,000 |
Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. (BNGO)